Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.68 |
| ▸ | MAPT | P10636 | 11/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.68 |
| ▸ | HPGD | P15428 | 11/20 | 0.68 |
| ▸ | NPC1 | O15118 | 11/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.68 |
| ▸ | MEN1 | O00255 | 10/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.68 |
| ▸ | RAB9A | P51151 | 9/20 | 0.68 |
| ▸ | TP53 | P04637 | 7/20 | 0.68 |
| ▸ | GAA | P10253 | 7/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.68 |
| ▸ | RELA | Q04206 | 2/20 | 0.68 |
| ▸ | APP | P05067 | 1/20 | 0.68 |
| ▸ | SNCA | P37840 | 1/20 | 0.68 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 6/20 | 0.61 |
| ▸ | GFER | P55789 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9032997 | 0.92 | ALDH1A1 (0.62) | ALDH1A1MAPTSMN1; SMN2HPGDNPC1 | |
| SCHEMBL2246334 | 0.90 | ALDH1A1 (0.77) | ALDH1A1MAPTSMN1; SMN2HPGDNPC1 | |
| SCHEMBL3335014 | 0.90 | ALDH1A1 (0.61) | ALDH1A1MAPTSMN1; SMN2HPGDNPC1 | |
| Hydrochloric Acid SCHEMBL3199354 | 0.89 | ALDH1A1 (0.75) | ALDH1A1MAPTSMN1; SMN2HPGDNPC1 | |
| SCHEMBL27202473 | 0.87 | ALDH1A1 (0.82) | ALDH1A1MAPTSMN1; SMN2HPGDNPC1 | |
| SCHEMBL159873 | 0.86 | ALDH1A1 (0.74) | ALDH1A1MAPTSMN1; SMN2HPGDNPC1 | |
| SCHEMBL28312335 | 0.86 | ALDH1A1 (0.74) | ALDH1A1MAPTSMN1; SMN2HPGDNPC1 | |
| SCHEMBL9862039 | 0.86 | ALDH1A1 (0.69) | ALDH1A1MAPTSMN1; SMN2HPGDNPC1 | |
| SCHEMBL30307784 | 0.86 | ALDH1A1 (0.74) | ALDH1A1MAPTSMN1; SMN2HPGDNPC1 | |
| SCHEMBL30533210 | 0.84 | MEN1 (0.73) | ALDH1A1MAPTSMN1; SMN2HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1204652-B1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6649642-B2 | Useful in the treatment of autoimmune and other cathepsin related diseases. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030087939-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1204652-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-05-15 | — | — | EP | disclosed |
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | BEKKALI YOUNES (US) | 2001-11-15 | — | — | US | disclosed |
| US-6313117-B1 | TREATING AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001009110-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | SDHA, LONP1, SUCNR1 | ALDH1A1 586/4885MAPT 4521/4885SMN1; SMN2 3942/4885 |
| US-20030087939-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | SDHA, LONP1, SUCNR1 | ALDH1A1 586/4885MAPT 4521/4885SMN1; SMN2 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.